The incidence and mortality of COVID-19 related TB disease in Sub-Saharan Africa: A systematic review and meta-analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
Coronavirus disease 2019 (COVID-19) is also associated with other co-morbidities in people who have previously or currently have pulmonary tuberculosis (PTB). PTB is a risk factor for COVID-19, both in terms of severity and mortality, regardless of HIV status. However, there is less information available on COVID-19 and PTB in terms of incidence and mortality rates in Sub-Saharan Africa (SSA), a high-burden TB region. This systematic review provided a data synthesis of available evidence on COVID-19/PTB incidence and case fatality rates, as well as mortality rates found in clinical and post-mortem COVID-19/PTB diagnostics in SSA.
Methods
We conducted an electronic search in the PubMed, Medline, Google Scholar, Medrxix, and COVID-19 Global literature on coronavirus disease databases for studies involving COVID-19 and PTB in Sub-Saharan Africa. The primary outcomes were the incidence proportion of people with COVID-19 who had current or previous PTB, as well as the case fatality rate associated with COVID-19/PTB. Based on methodological similarities in the included random effect model studies, the combination method was developed using Stata version 16 and Prometa 3 software. We also performed sensitivity analysis and meta-regression.
Results
From the 548 references extracted by the literature search, 25 studies were selected and included in the meta-analysis with a total of 191, 250 COVID-19 infected patients and 11, 480 COVID-19 deaths. The pooled COVID-19/PTB incidence was 3% [2%-5%] and a case fatality rate of 13% [4%-23%]. The pooled estimates for case fatality rate among COVID-19/PTB were 7% [1%-12%] for clinical PTB diagnostic and 25% [3%-47%] for post-mortem PTB diagnostic. Previous TB had the highest incidence and fatality rates with 46 [19-73] per 1, 000 population and 8% [3%-19%], respectively. Meta-regression model including the effect sizes and cumulative COVID-19 cases (P= 0.032), HIV prevalence (P= 0.041), and TB incidence (P= 0.002) to explain high heterogeneity between studies.
Conclusion
To summarize, the incidence of TB associated with COVID-19 is higher in SSA, as are the case fatality rates, when compared to the rest of the world. However, because the post-mortem TB diagnostic was higher, COVID-19 associated with TB may have been underreported in studies conducted in SSA. To confirm COVID-19/TB incidence and case fatality rates in SSA, large-scale cohort studies that adequately clear tools on previous and/or current TB diagnostic tools are required.
Review registration
PROSPERO (CRD42021233387)
Article activity feed
-
-
SciScore for 10.1101/2022.01.11.22269065: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Search strategy and eligibly criteria: A search of the literature was systematically conducted using Pubmed, Medline, Google Scholar, Medrxix and COVID-19 Global literature on coronavirus disease. Pubmedsuggested: (PubMed, RRID:SCR_004846)Medlinesuggested: (MEDLINE, RRID:SCR_002185)Google Scholarsuggested: (Google Scholar, RRID:SCR_008878)The search was restricted to studies related to the incidence and case fatality rates of COVID-19 related to TB in SSA since December 2019 to November 2021 including the … SciScore for 10.1101/2022.01.11.22269065: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Search strategy and eligibly criteria: A search of the literature was systematically conducted using Pubmed, Medline, Google Scholar, Medrxix and COVID-19 Global literature on coronavirus disease. Pubmedsuggested: (PubMed, RRID:SCR_004846)Medlinesuggested: (MEDLINE, RRID:SCR_002185)Google Scholarsuggested: (Google Scholar, RRID:SCR_008878)The search was restricted to studies related to the incidence and case fatality rates of COVID-19 related to TB in SSA since December 2019 to November 2021 including the key words and term as follows: “Covid-19 or 2019-nCoV or coronavirus disease 2019 or Novel coronavirus or SARS-CoV-2 “ and “tuberculosis or PTB or TB or Mycobacterium tuberculosis infection” and “mortality rate or death rate or case fatality rate” and “incidence or Incidence proportions or Incidence rate or incidence rate or attack rate” and “Angola or Benin or Botswana or Burkina Faso or Burundi or Cameroon or Cape Verde or “Central African republic” or Chad or Congo or “Democratic Republic of Congo” or DRC or Djibouti or Equatorial guinea or Eritrea or Ethiopia or Gabon or Gambia or Ghana or Guinea or Bissau or Ivory coast or ““Cote d’ ivoire” or Kenya or Lesotho or Liberia or Madagascar or Malawi or Mali or Mayotte or Mozambique or Namibia or Niger or Nigeria or Principe or Reunion or Rhodesia or Rwanda or “Sao Tome” or Senegal or “Sierra Leone” or Somalia or “South Africa” or Swaziland or Tanzania or Togo or Uganda or Zambia or Zimbabwe or “Central Africa” or “Sub-Saharan Africa” or “East Africa” or “Southern Africa” or “South Africa”, without language restrictions to identify citations from prior to January 2020. Madagascarsuggested: (Madagascar, RRID:SCR_003274)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-